WikipediA

Anakinra

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease.^[3] It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein.^[3] It is marketed by Swedish Orphan Biovitrum.^[1] Anakinra is administered by subcutaneous injection.^[2]

Contents

Medical uses

Safety

Adverse effects

Chemistry

History

Society and culture Legal status

Research COVID-19

References


External links

Medical uses

It is used as a second line treatment to manage symptoms of rheumatoid arthritis after treatment with a diseasemodifying antirheumatic drug (DMARD) has failed. $\underline{[1][2]}$ It can be used in combination with some DMARDs. $\underline{[1][2][4]}$

It is used to people with a cryopyrin-associated periodic syndrome, including neonatal-onset multisystem inflammatory disease. [1][2]

It is used to treat <u>Schnitzler's syndrome</u> (off label in the US).^[5] Its response rate is such that it has been suggested that "Treatment failures should lead to reconsider the diagnosis."^[6]



https://en.wikipedia.org/wiki/Anakinra

Off label, it is used to treat systemic juvenile idiopathic arthritis (SJIA), gout, calcium pyrophosphate deposition (CPPD), Behçet's disease, ankylosing spondylitis, uveitis, and other auto-inflammatory syndromes.^[7]

In December 2021, the <u>European Medicines Agency</u> authorized the use of anakinra "to treat <u>COVID-19</u> in adults with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng per ml."[3][8][9]

Safety

It was not tested in pregnant women, but appeared to be safe in animal studies. $\underline{[2]}$

It should not be used in people who have active infections or latent tuberculosis, who have low white blood cells counts, or who are taking $\underline{\text{TNF}}$ inhibitors.^[2]

Adverse effects

More than ten percent of people taking Anakinra have injection site reactions, headaches, and have increased cholesterol levels.^[1] Between one and ten percent of recipients have severe infections, decreased white blood cells, or decreased <u>platelets</u>.^[1] It is unclear if taking Anakinra increases cancer risk; studies are complicated by the fact that people with rheumatoid arthritis already face higher cancer risk.^{[1][4]}

Chemistry

Anakinra differs from the sequence of Interleukin 1 receptor antagonist by one methionine amino acid added to its <u>N-terminus</u>; it also differs from the human protein in that it is not glycosylated, as it is <u>manufactured</u> in *Escherichia coli*.^[2]

History

It was approved for medical use in the US in 2001, $\underline{[2]}$ and in the European Union in 2002. $\underline{[1][3]}$

kipedia							
	US DailyMed: Anakinra (https://dailymed.nlm.ni h.gov/dailymed/search. cfm?labeltype=all&que ry=Anakinra)						
Pregnancy category	<u>AU</u> : B1						
Routes of administration	Subcutaneous						
ATC code	L04AC03 (WHO (http s://www.whocc.no/atc_ ddd_index/?code=L04 AC03))						
Legal status							
Legal status	AU: S4 (Prescription only)						
	<u>CA</u> : <u>R-only</u>						
	<u>UK</u> : <u>POM</u> (Prescription only) [1]						
	<u>US</u> : <u>R-only</u> ^[2]						
	<u>EU</u> : Rx-only ^[3]						
Pharma	cokinetic data						
Bioavailability	95%						
Metabolism	predominantly kidney						
Elimination half-life	4-6 hrs						
Ide	entifiers						
IUPAC name							
Recombinant huma	n Interleukin-1 receptor a						
ntagonist protei	n; syn. N2-I-methionyl-int						
	tor antagonist (human is						
oform x reduced	1)						
CAS Number	143090-92-0 (https://c						
	ommonchemistry.cas.o						
	rg/detail?cas_rn=1430						
	90-92-0) ✓						
DrugBank	DB00026 (https://www.						
	drugbank.ca/drugs/DB						
	00026) ✓						
ChemSpider	none						
UNII	9013DUQ28K (https://						

Anakinra - Wikipedia

In 2018, NHS England published a *Clinical Commissioning* Policy: Anakinra periodic to treat fevers autoinflammatory disorders (all ages) allowing Anakinra to be commissioned as a first-line treatment for Schnitzler's syndrome and in cases where the first-line treatment is not effective for Familial Mediterranean fever, Hyper-IgD syndrome also known as Mevalonate kinase deficiency, and TNF receptor associated periodic syndrome (TRAPS), [10] Clinical Commissioning and Policy: а Anakinra/tocilizumab for the treatment of Adult-Onset Still's Disease refractory to second-line therapy (adults), allowing Anakinra to be commissioned for adult-onset Still's disease "as a third line treatment where patients are refractory to steroid-sparing effect DMARDs".^[11]

In December 2020, Anakinra was approved by the US Food and Drug Administration for the treatment of deficiency of the interleukin-1–receptor antagonist (DIRA), a rare autoinflammatory disease of infancy.^[12] In 2021, it was

	precision.fda.gov/uniis earch/srs/unii/9013DU Q28K <u>)</u>					
KEGG	D02934 (https://www.k egg.jp/entry/D02934) ✓					
<u>ChEMBL</u>	ChEMBL1201570 (http s://www.ebi.ac.uk/che mbldb/index.php/comp ound/inspect/ChEMBL 1201570) X					
Chemical and physical data						
Formula	$C_{759}H_{1186}N_{208}O_{232}S_{10}$					
Molar mass	17 257.66 g·mol ^{−1}					
✓ (what is this?) (verify)						

announced that the Ministry of Health of the Russian Federation had approved the use of Anakinra for the treatment of CAPS.^[13]

In October 2021, NHS England published *Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages*, allowing Anakinra to be used in the treatment of HLH.^[14]

Society and culture

Legal status

	Approvals										
	Condition										
Country	RA	CAPS	FMF	AOSD	Schnitzler's	MKD	TRAPS	DIRA	HLH		
US	2001							2020			
UK				2018	2018	2018	2018		2021		
EU	2002	2002	2002								
Russia		2021									

Research

Anakinra effectively treated meningitis caused by a rare genetic mutation in the gene <u>NALP3</u> in a 67year-old man enrolled in the <u>Undiagnosed Diseases Network.^[15]</u> Researchers at <u>Johns Hopkins</u> <u>University</u> announced in 2019 that anakinra given to pregnant mice with <u>Zika virus</u> had reduced fetal deaths and birth defects.^[16] In November 2019, researchers at the <u>University of Manchester</u> reported that Anakinra might have a use in preventing breast cancer from spreading to the bones.^{[17][18]}

Anakinra - Wikipedia

In 2021, it was reported that Anakinra appeared to reduce the <u>neuropathic pain</u> experienced by patients undergoing <u>chemotherapy</u> with <u>vincristine</u>, saying that "repurposing anakinra may be an effective co-treatment strategy to prevent vincristine-induced peripheral neuropathy".^{[19][20]}

A review published in 2022 found that "Anakinra appears to show efficacy for numerous dermatologic conditions, with the strongest evidence for <u>hidradenitis</u> suppurativa, <u>Behçet's disease</u>, <u>Muckle–Wells</u> syndrome, and <u>SAPHO syndrome</u>." and concluded that "Overall, anakinra appears to be a promising option in the treatment of numerous dermatologic inflammatory conditions refractory to first line therapies, but further and higher-quality data is needed to clarify its therapeutic role."^[21]

COVID-19

Anakinara is undergoing multiple clinical trials to treat <u>COVID-19</u> patients, by targeting mechanisms in patients with hyperinflammation.^[22] In 2021 a review and <u>meta-analysis</u> of 9 studies involving 1,119 cases concluded that "Available evidence shows that treatment with anakinra reduces both the need for invasive mechanical ventilation and mortality risk of hospitalized non-intubated patients with COVID-19 without increasing the risk of adverse events."^[23]

As of July 2021, the European Medicines Agency (EMA) is evaluating an application to extend the use of anakinra to include treatment of <u>COVID-19</u> in adults with pneumonia who are at risk of developing severe respiratory failure (inability of the lungs to work properly).^[24] According to study results published in September 2021 in <u>Nature Medicine</u>, hospitalized COVID-19 patients at increased risk for respiratory failure showed significant improvement after treatment with Anakinra.^{[25][26]}

References

- "Kineret 100 mg solution for injection in a pre-filled syringe Summary of Product Characteristics (SmPC)" (https://www.medicines.org.uk/emc/product/559). UK Electronic Medicines Compendium. Retrieved 2 March 2022.
- "Kineret- anakinra injection, solution" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d 9d74915-6606-4570-9c52-c4001d3177de). DailyMed. 30 December 2020. Retrieved 2 March 2022.
- "Kineret EPAR" (https://www.ema.europa.eu/en/medicines/human/EPAR/kineret). European Medicines Agency. Retrieved 20 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. (May 2016). "Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network metaanalysis" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068903). The Cochrane Database of Systematic Reviews. 2016 (5): CD012183. doi:10.1002/14651858.CD012183 (https://doi.org/10.1 002%2F14651858.CD012183). PMC 7068903 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC70 68903). PMID 27175934 (https://pubmed.ncbi.nlm.nih.gov/27175934).
- Gusdorf L, Lipsker D (August 2017). "Schnitzler Syndrome: a Review". *Current Rheumatology Reports.* **19** (8): 46. doi:10.1007/s11926-017-0673-5 (https://doi.org/10.1007%2Fs11926-017-067 3-5). PMID 28718061 (https://pubmed.ncbi.nlm.nih.gov/28718061). <u>S2CID</u> 13780498 (https://api.s emanticscholar.org/CorpusID:13780498).

- Néel, Antoine; et al. (October 2014). "Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study". <u>Autoimmunity</u> <u>Reviews</u>. 13 (10): 1035–1041. doi:10.1016/j.autrev.2014.08.031 (https://doi.org/10.1016%2Fj.autr ev.2014.08.031).
- 7. "Anakinra (Kineret)" (https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Anakinr a-Kineret). American College of Rheumatology. Retrieved 2021-11-22.
- "EMA recommends approval for use of Kineret in adults with COVID-19" (https://www.ema.europ a.eu/en/news/ema-recommends-approval-use-kineret-adults-covid-19). European Medicines Agency. 16 December 2021. Retrieved 2 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Aripaka, Pushkala; Karimi, Amna (16 December 2021). "EU regulator builds Omicron defences with approvals of GSK-Vir, Sobi drugs" (https://www.reuters.com/business/healthcare-pharmaceuti cals/eu-regulator-okays-covid-19-treatments-gsk-vir-sobi-2021-12-16/). Reuters. Retrieved 17 December 2021.
- NHS England (29 June 2018). <u>Clinical Commissioning Policy: Anakinra to treat periodic fevers</u> and autoinflammatory disorders (all ages) (https://www.england.nhs.uk/wp-content/uploads/2018/ 07/1713-anakinra-for-periodic-fever.pdf) (PDF). Retrieved 9 July 2018.
- NHS England (29 June 2018). <u>Clinical Commissioning Policy: Anakinra/tocilizumab for the</u> treatment of Adult-Onset Still's Disease refractory to second-line therapy (adults) (https://www.eng land.nhs.uk/wp-content/uploads/2018/07/1609-anakinra-and-tocilizumab-for-aosd.pdf) (PDF). Retrieved 13 July 2018.
- 12. Kaufman, Michelle B. (2 February 2021). "FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease" (https://www.the-rheumatologist.org/article/fda-approves-new-rituximab-bio similar-anakinra-to-treat-a-rare-disease/). *The Rheumatologist*. Retrieved 4 February 2021.
- "Kineret approved in Russia for the treatment of CAPS" (https://www.thepharmaletter.com/article/k ineret-approved-in-russia-for-the-treatment-of-caps). The Pharma Letter. 17 February 2021. Retrieved 18 February 2021.
- NHS England (October 2021). <u>Clinical Commissioning Policy: Anakinra for Haemophagocytic</u> <u>Lymphohistiocytosis (HLH) for adults and children in all ages (https://www.england.nhs.uk/wp-cont</u> ent/uploads/2021/10/1924-Clinical-commissioning-policy-anakinra-for-haemophagocytic-lymphohi stiocytosis-1.pdf) (PDF). Retrieved 14 October 2021.
- Kolata G (2019-01-07). "When the Illness Is a Mystery, Patients Turn to These Detectives" (https:// www.nytimes.com/2019/01/07/health/patients-medical-mysteries.html). The New York Times. Retrieved 2019-01-09.
- 16. "Rheumatoid Arthritis Drug Diminishes Zika Birth Defects in Mice" (https://www.hopkinsmedicine.o rg/news/newsroom/news-releases/rheumatoid-arthritis-drug-diminishes-zika-birth-defects-inmice). *Newsroom*. Johns Hopkins Medicine. 6 May 2019. Retrieved 5 September 2019.
- "Arthritis drugs could be repurposed to help prevent breast cancer spreading to the bone, study suggests" (https://www.manchester.ac.uk/discover/news/arthritis-drugs-could-be-repurposed-to-he lp-prevent-breast-cancer-spreading-to-the-bone-study-suggests/). Press release. University of Manchester. 20 November 2019. Retrieved 21 November 2019.
- Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, et al. (November 2019). "Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825219). Nature Communications. 10 (1): 5016. Bibcode:2019NatCo..10.5016E (https://ui.adsabs.harvard.edu/ab s/2019NatCo..10.5016E). doi:10.1038/s41467-019-12807-0 (https://doi.org/10.1038%2Fs41467-0 19-12807-0). PMC 6825219 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825219). PMID 31676788 (https://pubmed.ncbi.nlm.nih.gov/31676788).

- Starobova H, Monteleone M, Adolphe C, Batoon L, Sandrock CJ, Tay B, et al. (May 2021). "Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933984). The Journal of Experimental Medicine. 218 (5): e20201452. doi:10.1084/jem.20201452 (https://doi.org/10.1084%2Fjem.20201 452). PMC 7933984 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933984). PMID 33656514 (https://pubmed.ncbi.nlm.nih.gov/33656514).
- 20. "Chemotherapy with fewer side effects may be on the way" (https://www.uq.edu.au/news/article/2 021/02/chemotherapy-fewer-side-effects-may-be-way-0). University of Queensland. 15 March 2021. Retrieved 15 March 2021.
- 21. Tegtmeyer, Kyle; et al. (2 January 2022). "Off-Label studies on anakinra in dermatology: a review". Journal of Dermatological Treatment. **33** (1): 73–86. doi:10.1080/09546634.2020.1755417 (https:// doi.org/10.1080%2F09546634.2020.1755417).
- 22. "Anakinra in COVID-19: important considerations for clinical trials" (https://www.researchgate.net/ publication/341554901). Press release. May 2020. Retrieved 5 January 2021.
- 23. Barkas, Fotios; Ntekouan, Sebastian Filippas; Kosmidou, Maria; Liberopoulos, Evangelos; Liontos, Angelos; Milionis, Haralampos (2021-05-17). <u>"Anakinra in hospitalized non-intubated</u> patients with coronavirus disease 2019: a systematic review and meta-analysis" (https://www.ncbi. nlm.nih.gov/pmc/articles/PMC8194671). *Rheumatology*. **60** (12): 5527–5537. doi:10.1093/rheumatology/keab447 (https://doi.org/10.1093%2Frheumatology%2Fkeab447). PMC 8194671 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194671). <u>PMID</u> 33999135 (https:// pubmed.ncbi.nlm.nih.gov/33999135).
- 24. "EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk severe respiratory failure" (https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-kineret-adult-c ovid-19-patients-increased-risk-severe-respiratory-failure). *European Medicines Agency (EMA)* (Press release). 16 July 2021. Retrieved 20 July 2021.
- 25. Kyriazopoulou, Evdoxia; Poulakou, Garyfallia; Milionis, Haralampos; Metallidis, Simeon; Adamis, Georgios; Tsiakos, Konstantinos; Fragkou, Archontoula; Rapti, Aggeliki; Damoulari, Christina; Fantoni, Massimo; Kalomenidis, Ioannis (2021-09-03). <u>"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516650). *Nature Medicine*. **27** (10): 1752–1760. doi:10.1038/s41591-021-01499-z (https://doi.org/10.1038% 2Fs41591-021-01499-z). ISSN 1078-8956 (https://www.worldcat.org/issn/1078-8956). PMC 8516650 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516650). PMC 8516650 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516650).</u>
- 26. "Anakinra improved survival in hospitalized COVID-19 patients" (https://www.mdedge.com/rheum atology/article/245801/coronavirus-updates/anakinra-improved-survival-hospitalized-covid-19). www.mdedge.com. Retrieved 2021-09-09.

External links

 "Anakinra" (https://druginfo.nlm.nih.gov/drugportal/name/anakinra). Drug Information Portal. U.S. National Library of Medicine.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Anakinra&oldid=1100703266"

This page was last edited on 27 July 2022, at 07:21 (UTC).

Text is available under the Creative Commons Attribution-ShareAlike License 3.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.

8/22/22, 5:33 AM

Anakinra - Wikipedia